Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.

@article{Korytkowski2002GlimepirideIB,
  title={Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.},
  author={M. Korytkowski and Abraham Thomas and Lynn Reid and M. B. Tedesco and W. Gooding and J. Gerich},
  journal={Diabetes care},
  year={2002},
  volume={25 9},
  pages={
          1607-11
        }
}
OBJECTIVE The purpose of this study was to assess the effect of glimepiride on insulin sensitivity and secretion in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS After a 2-week washout from prior sulfonylurea therapy, 11 obese subjects with type 2 diabetes underwent euglycemic and hyperglycemic clamp studies before and during glimepiride therapy. RESULTS Glimepiride resulted in a 2.4-mmol/l decrease in fasting plasma glucose (P = 0.04) that was correlated with reductions in… Expand
Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.
Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes.
Glimepiride: evidence-based facts, trends, and observations
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects.
Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin-dependent diabetes mellitus.
The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
  • H. E. Clark, D. Matthews
  • Medicine
  • Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
  • 1996
Mechanism of improvement in glucose metabolism after chronic glyburide therapy.
...
1
2
3
4
...